Hillcrest Asset Management LLC grew its stake in shares of Emergent Biosolutions Inc (NYSE:EBS) by 36.4% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 184,958 shares of the biopharmaceutical company’s stock after acquiring an additional 49,322 shares during the quarter. Hillcrest Asset Management LLC owned about 0.36% of Emergent Biosolutions worth $9,344,000 as of its most recent SEC filing.
Several other large investors also recently added to or reduced their stakes in the company. Rehmann Capital Advisory Group grew its stake in Emergent Biosolutions by 78.7% in the fourth quarter. Rehmann Capital Advisory Group now owns 452 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 199 shares during the period. Quantamental Technologies LLC acquired a new stake in Emergent Biosolutions in the fourth quarter valued at approximately $29,000. Semmax Financial Advisors Inc. acquired a new stake in Emergent Biosolutions in the fourth quarter valued at approximately $30,000. Pearl River Capital LLC acquired a new stake in Emergent Biosolutions in the first quarter valued at approximately $34,000. Finally, Bronfman E.L. Rothschild L.P. lifted its holdings in shares of Emergent Biosolutions by 1,108.7% in the fourth quarter. Bronfman E.L. Rothschild L.P. now owns 1,112 shares of the biopharmaceutical company’s stock valued at $66,000 after purchasing an additional 1,020 shares in the last quarter. Hedge funds and other institutional investors own 86.42% of the company’s stock.
A number of research analysts have recently weighed in on EBS shares. Zacks Investment Research lowered Emergent Biosolutions from a “buy” rating to a “hold” rating in a report on Monday, April 8th. Cantor Fitzgerald restated a “buy” rating and issued a $75.00 target price on shares of Emergent Biosolutions in a report on Thursday, May 2nd. Wells Fargo & Co set a $68.00 price target on Emergent Biosolutions and gave the stock a “hold” rating in a report on Tuesday, April 2nd. ValuEngine lowered Emergent Biosolutions from a “hold” rating to a “sell” rating in a report on Wednesday, March 20th. Finally, TheStreet lowered Emergent Biosolutions from a “b+” rating to a “c+” rating in a report on Tuesday, March 12th. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $68.86.
Emergent Biosolutions stock traded down $0.58 during midday trading on Wednesday, hitting $46.53. 378,861 shares of the company’s stock were exchanged, compared to its average volume of 495,478. Emergent Biosolutions Inc has a 52-week low of $39.64 and a 52-week high of $73.89. The stock’s 50-day moving average price is $44.66. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.28 and a current ratio of 2.13. The firm has a market capitalization of $2.35 billion, a P/E ratio of 19.97, a P/E/G ratio of 0.75 and a beta of 1.52.
Emergent Biosolutions (NYSE:EBS) last issued its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.13 by ($0.26). Emergent Biosolutions had a return on equity of 11.73% and a net margin of 4.88%. The firm had revenue of $190.60 million for the quarter, compared to the consensus estimate of $201.36 million. During the same period last year, the firm earned ($0.03) EPS. The company’s revenue for the quarter was up 61.8% on a year-over-year basis. As a group, research analysts expect that Emergent Biosolutions Inc will post 3.06 earnings per share for the current year.
In other news, Director Kathryn C. Zoon sold 1,376 shares of the business’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $43.39, for a total value of $59,704.64. Following the completion of the sale, the director now owns 24,379 shares of the company’s stock, valued at approximately $1,057,804.81. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 14.10% of the company’s stock.
Emergent Biosolutions Profile
Emergent BioSolutions Inc, a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids.
See Also: Why are trading ranges significant?
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.